Analysis of Olaparib API Olaparib API Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
According to a new industry report released by Fact.MR, revenue from the global olaparib API market is estimated at US$ 1.07 billion in 2024 and has been evaluated to increase at an excellent CAGR of 15.3% through 2034 to achieve a value of US$ 4.41 billion by the end of 2034.
Olaparib belongs to the expanding class of PARP inhibitors, which are becoming more popular as successful precision oncology treatments. Because olaparib API is used in targeted therapy, its demand is rising as personalized medicine is gaining traction worldwide. Olaparib's use is extended beyond ovarian cancer to encompass pancreatic, prostate, and breast cancers due to approvals from regulatory agencies, such as the FDA and EMA.
The need for APIs is increasing owing to this wider range of applications. Olaparib's potential use in combination therapies and for other cancer types is investigated by pharmaceutical companies through significant investments in research and clinical trials, which is driving up demand for its API.
In 2024, the North American region is approximated to hold 37% of the global market share. North America is leading because of its strong healthcare systems and high adoption rate of advanced cancer treatment solutions. The FDA's regulatory approvals for Olaparib for several cancer types, such as breast, prostate, ovarian, and others are driving up demand for the medication.
By indication, the ovarian cancer segment is projected to account for a 48.2% portion of the market in 2024. This segment holds a significant market share due to olaparib's proven efficacy in treating ovarian cancer with BRCA mutations. At first, olaparib was authorized for the treatment of ovarian cancer, namely in patients with germline or somatic BRCA mutations. It is a recommended therapy because of its proven ability to extend the patients' progression-free survival.
| Report Attributes | Details |
|---|---|
| Olaparib API Market Size (2024E) | US$ 1.07 Billion |
| Forecasted Market Value (2034F) | US$ 4.41 Billion |
| Global Market Growth Rate (2024 to 2034) | 15.3% CAGR |
| North America Market Share (2024E) | 37% |
| Western Europe Market Value (2024E) | US$ 227.4 Million |
| South Asia & Pacific Market Growth Rate (2024 to 2034) | 18.2% CAGR |
| Ovarian cancer Segment Value (2034F) | US$ 2.22 Billion |
| Contract Manufacturing Organizations (CMOs) Segment Value (2034F) | US$ 2.61 Billion |
| Key Companies Profiled | ScinoPharm Taiwan, Ltd.; Transo-Pharm USA LLC; ALP Pharm Beijing Co., Ltd; MSN Laboratories Pvt Ltd; Alembic Pharmaceuticals Limited; Exelixis Inc.; Pfizer Inc.; AstraZeneca plc.; Novartis AG; Bayer AG.; Dr. Reddy's Laboratories; Sun Pharmaceutical Industries |
Olaparib is used in the treatment of advanced epithelial ovarian cancer, breast cancer, and pancreatic cancer. Olaparib with bevacizumab during ovarian cancer chemotherapy. Olaparib API is a pharmaceutical ingredient used in the manufacturing of Olaparib drugs for various disorders like breast cancer, pancreatic cancer, and ovarian cancer. According to the WHO, in 2018 there were around 627,000 women died from breast cancer. The rising prevalence of cancer is expected to raise the demand for Olaparib API in the global market.
Most of the Key players focus on developing coronavirus treatment and diagnostic kits, which will hinder Olaparib API market growth. Pharmaceutical and biopharmaceutical companies have shifted their focus to developing coronavirus diagnostic kits and treatment options, which will hamper the market growth.
The increasing prevalence of breast cancer, ovarian cancer, and prostate cancer is expected to drive the olaparib API market share. The rise in the number of manufacturers and domestic players in the Asia-Pacific region will boost the olaparib API market growth. Growing Instances of Cancer Patients, drastic changes in eating habits and lifestyle propel the risk of disease and hence will increase demand for Olaparib API. Significant adoption of Olaparib API products in Pharmaceutical Products Manufacturing also boosts the market growth.
Tremendous increases in healthcare expenditure will propel the market during the forecast period. Introduction to highly advanced and safe active pharmaceutical ingredients will lead to a rise in product demand in the coming decade. However, side effects associated with olaparib API will hinder the olaparib API market growth over the forecast period. The higher production cost of Olaparib API will hamper overall business growth. Moreover, technological advancement and research and development API lead to potential Threats of Substitutes for Olaparib API.
The global increase in olaparib API market consolidation activities such as new setting of new manufacturing facilities or capacity expansion. Olaparib API manufacturing development, mergers & acquisitions, and services agreements will aid in substantial market potential. Moreover, Key manufacturers with the intent to expand their services and distribution network look for emerging nations as lucrative markets for investments. Olaparib API therapeutics currently represent the most promise and have experienced the most success within the overall class.
North America is leading due to a higher rate of adaption of Olaparib API in the treatment of cancer. The USA and Europe have been so far successful in drug development for cancer, especially breast cancer and Prostate Cancer. Increasing innovative API therapeutics, and investment for research in the fields of cancer to minimize the side effects of Olaparib API. Other regions are expected to grow in the olaparib API market due to increasing expenditure on healthcare. Untapped markets in emerging economies such as Asia and Latin America should be one of the top priorities for global Olaparib API manufacturers to increase their services and revenue in the market.
Some of the key market players in the olaparib API industry are ScinoPharm Taiwan, Ltd, Transo-Pharm USA LLC, ALP Pharm Beijing Co., Ltd, MSN Laboratories Pvt Ltd, Alembic Pharmaceuticals Limited, Exelixis Inc, Pfizer Inc, AstraZeneca plc, Novartis AG and Bayer AG.
The research report on Olaparib API presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on Olaparib API provides analysis and information according to market segments such as geographies, applications, and industry.
The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
What are the factors fueling the sales of Olaparib APIs?
Demand for olaparib APIs is increasing due to the rising prevalence of breast cancer, ovarian cancer, and prostate cancer across the world.
Which region is dominating global market growth?
North America is in the lead because there is high use of olaparib APIs for cancer treatment.
Who are the major players in the olaparib API market?
ScinoPharm Taiwan, Ltd, Transo-Pharm USA LLC, ALP Pharm Beijing Co. Ltd, Pfizer Inc, AstraZeneca plc, and Novartis AG are prominent olaparib API producers.
Olaparib API Market